These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 2693167)
41. Natural course of insulin sensitivity and insulin reserve in early insulin-dependent diabetes mellitus. Linn T; Ebener K; Raptis G; Laube H; Federlin K Metabolism; 1995 May; 44(5):617-23. PubMed ID: 7752910 [TBL] [Abstract][Full Text] [Related]
42. C-peptide and free insulin determinations in type I diabetes; relationships with metabolic control and insulin therapy. Taskinen MR; Groop L Ann Clin Res; 1984; 16(2):118-27. PubMed ID: 6380385 [No Abstract] [Full Text] [Related]
43. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Chaillous L; Lefèvre H; Thivolet C; Boitard C; Lahlou N; Atlan-Gepner C; Bouhanick B; Mogenet A; Nicolino M; Carel JC; Lecomte P; Maréchaud R; Bougnères P; Charbonnel B; Saï P Lancet; 2000 Aug; 356(9229):545-9. PubMed ID: 10950231 [TBL] [Abstract][Full Text] [Related]
44. Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Nakanishi K; Kobayashi T; Miyashita H; Ohkubo M; Sugimoto T; Murase T; Kosaka K; Inouye K; Kono M Metabolism; 1990 Sep; 39(9):925-30. PubMed ID: 2202883 [TBL] [Abstract][Full Text] [Related]
45. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229 [TBL] [Abstract][Full Text] [Related]
46. Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes. Di Bonito P; De Bellis A; Capaldo B; Turco S; Corigliano G; Pace E; Bizzarro A Acta Diabetol; 1996 Sep; 33(3):220-4. PubMed ID: 8904929 [TBL] [Abstract][Full Text] [Related]
48. Clinical trials of cyclosporin in IDDM. Dupré J; Stiller CR; Gent M; Donner A; von Graffenried B; Heinrichs D; Jenner M; Keown P; Mahon J; Martell R Diabetes Care; 1988; 11 Suppl 1():37-44. PubMed ID: 3069390 [TBL] [Abstract][Full Text] [Related]
49. Interventions for latent autoimmune diabetes (LADA) in adults. Brophy S; Brunt H; Davies H; Mannan S; Williams R Cochrane Database Syst Rev; 2007 Jul; (3):CD006165. PubMed ID: 17636829 [TBL] [Abstract][Full Text] [Related]
50. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Landin-Olsson M; Nilsson KO; Lernmark A; Sundkvist G Diabetologia; 1990 Sep; 33(9):561-8. PubMed ID: 2253834 [TBL] [Abstract][Full Text] [Related]
51. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Andersson A; Borg H; Hallberg A; Hellerström C; Sandler S; Schnell A Diabetologia; 1984 Jul; 27 Suppl():66-9. PubMed ID: 6383922 [TBL] [Abstract][Full Text] [Related]
52. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Greenbaum CJ Clin Immunol; 2002 Aug; 104(2):97-104. PubMed ID: 12165270 [TBL] [Abstract][Full Text] [Related]
53. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). Pozzilli P; Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Romiti A; Giovannini C; Lucentini L; Matteoli MC; Crinò A; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Suppa M; Sulli N; De Mattia G; Faldetta MR Eur J Endocrinol; 1997 Sep; 137(3):234-9. PubMed ID: 9330586 [TBL] [Abstract][Full Text] [Related]
57. B-cell secretion in non-diabetics and insulin-dependent diabetics. Heding LG; Ludvigsson J; Kasperska-Czyzykowa T Acta Med Scand Suppl; 1981; 656():5-9. PubMed ID: 7046350 [No Abstract] [Full Text] [Related]
58. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395 [TBL] [Abstract][Full Text] [Related]
59. Cyclosporine, in combination with other drugs, studied in insulin-dependent diabetes therapy. Raymond CA JAMA; 1988 Mar; 259(11):1609, 1613-4. PubMed ID: 3343762 [No Abstract] [Full Text] [Related]
60. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Assan R; Feutren G; Debray-Sachs M; Quiniou-Debrie MC; Laborie C; Thomas G; Chatenoud L; Bach JF Lancet; 1985 Jan; 1(8420):67-71. PubMed ID: 2857024 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]